Bone Biologics Co. (NASDAQ:BBLG – Get Free Report) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 48,600 shares, a drop of 86.2% from the September 30th total of 352,700 shares. Based on an average daily volume of 4,210,000 shares, the short-interest ratio is currently 0.0 days. Currently, 9.3% of the shares of the company are short sold.
Bone Biologics Trading Up 0.6 %
Shares of NASDAQ:BBLG opened at $1.73 on Friday. The company has a 50-day simple moving average of $1.66 and a 200 day simple moving average of $1.62. Bone Biologics has a 52-week low of $0.80 and a 52-week high of $10.56.
Bone Biologics (NASDAQ:BBLG – Get Free Report) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.39) by $0.72. On average, equities research analysts anticipate that Bone Biologics will post -3.17 earnings per share for the current year.
Bone Biologics Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Read More
- Five stocks we like better than Bone Biologics
- The Significance of Brokerage Rankings in Stock Selection
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the FTSE 100 index?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What is a support level?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.